Article info

Original research
Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis

Authors

  1. Correspondence to Dr N Jewel Samadder, Mayo Clinic Minnesota, Rochester, Minnesota, USA; Samadder.Jewel{at}mayo.edu; Dr Paul J Limburg; limburg.paul{at}mayo.edu
View Full Text

Citation

Samadder NJ, Foster N, McMurray RP, et al
Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis

Publication history

  • Received November 10, 2021
  • Accepted May 14, 2022
  • First published May 30, 2022.
Online issue publication 
January 05, 2023

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.